Skip to content
Parakho

Sanofi India Ltd

NSE SANOFIBSE 500674

Q3 FY25, unaudited

Revenue
₹514.90 Cr
Profit after tax
₹91.30 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ3 FY25vs a year agoFY25
Revenue from operations514.90—2,013.20
Other income5.90—16.50
Total income520.80—2,029.70
Employee benefit expense53.80—240.20
Finance costs0.40—1.50
Depreciation & amortisation9.60—36.70
Total expenses406.60—1,560.60
Profit before tax122.20—431.40
Tax expense30.90—117.70
Profit after tax91.30—413.30
Total comprehensive income98.50—420.50
Earnings per share
Earnings per share, basic₹39.64₹179.46
Earnings per share, diluted₹39.60₹179.46

Q3 FY25 and FY25 — unaudited, from the company’s filing with NSE. Source

Why the dash

Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.

Earnings call

Q1 FY27

Sanofi India reported quarter two 2026 results with diabetes business growth of close to 14%, driven by Toujeo and Soliqua, while the partnership business with Emcure and Cipla grew 2% in the quarter. Profit before tax and exceptional items rose 19% year-on-year to INR 112 crores from INR 94 crores, with margin improving to 27% of net sales from 24%. Management discussed export market challenges in Australia offset partly by other markets, and noted cash balance grew 34%.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 44 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 13 Aug 2026.